{"transactions":[{"id":728757,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T23:29:20.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":2987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":2987,"derivative":{"exercise_price":106.52,"exercise_date":"2027-05-28","expiration_date":"2036-05-28","underlying":"Common Stock","underlying_shares":2987},"source":{"system":"sec-edgar","filing":"0001529196-26-000006","document":"form4a-06232026_110617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000152919626000006/form4a-06232026_110617.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":756829,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T22:18:48.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":2987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":2987,"derivative":{"exercise_price":53.57,"exercise_date":"2027-05-28","expiration_date":"2036-05-28","underlying":"Common Stock","underlying_shares":2987},"source":{"system":"sec-edgar","filing":"0001529196-26-000004","document":"form4-06012026_100644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000152919626000004/form4-06012026_100644.xml","form_type":"4"}},{"id":756828,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:18:48.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's\ncommon stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,154 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":60267,"source":{"system":"sec-edgar","filing":"0001529196-26-000004","document":"form4-06012026_100644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000152919626000004/form4-06012026_100644.xml","form_type":"4"}},{"id":944208,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T00:10:35.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,276 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":58389,"source":{"system":"sec-edgar","filing":"0001529196-26-000002","document":"form4-01082026_120132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000152919626000002/form4-01082026_120132.xml","form_type":"4"}},{"id":1127397,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:44:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":3149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":3149,"derivative":{"exercise_price":94.87,"exercise_date":"2026-05-29","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":3149},"source":{"system":"sec-edgar","filing":"0001415889-25-015178","document":"form4-06022025_080609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015178/form4-06022025_080609.xml","form_type":"4"}},{"id":1127396,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:44:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":2108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,688 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":57221,"source":{"system":"sec-edgar","filing":"0001415889-25-015178","document":"form4-06022025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015178/form4-06022025_080609.xml","form_type":"4"}},{"id":1127395,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:44:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,580 restricted stock units that have not vested or been delivered to the Reporting Person. Reflects the amount of securities beneficially owned by the Reporting Person at the time of the transaction; after giving effect to the transactions reported on a Form 4 filed with the Securities and Exchange Commission on February 28, 2025, the amount of securities beneficially owned by the Reporting Person was 55,113."}],"balance_after":35800,"source":{"system":"sec-edgar","filing":"0001415889-25-015178","document":"form4-06022025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925015178/form4-06022025_080609.xml","form_type":"4"}},{"id":1238184,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T22:57:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Granted June 2, 2016 and fully vested one year after grant date."}],"balance_after":0,"derivative":{"exercise_price":24.69,"expiration_date":"2026-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-006046","document":"form4-02282025_100208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925006046/form4-02282025_100208.xml","form_type":"4"}},{"id":1238183,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T22:57:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted July 23, 2015. Vested 1/3 annually over a three-year period such that it vested in full on the three-year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":32,"expiration_date":"2025-07-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-006046","document":"form4-02282025_100208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925006046/form4-02282025_100208.xml","form_type":"4"}},{"id":1238182,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T22:57:12.000Z","date":"2025-02-26","kind":"sale","planned":false,"acquired":false,"shares":20687,"price":120.72,"value":2497334.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $120.59 to $121.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":54249,"source":{"system":"sec-edgar","filing":"0001415889-25-006046","document":"form4-02282025_100208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925006046/form4-02282025_100208.xml","form_type":"4"}},{"id":1238181,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T22:57:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":24.69,"value":370350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":74936,"source":{"system":"sec-edgar","filing":"0001415889-25-006046","document":"form4-02282025_100208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925006046/form4-02282025_100208.xml","form_type":"4"}},{"id":1238180,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T22:57:12.000Z","date":"2025-02-26","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":32,"value":800000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,716 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":59936,"source":{"system":"sec-edgar","filing":"0001415889-25-006046","document":"form4-02282025_100208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588925006046/form4-02282025_100208.xml","form_type":"4"}},{"id":1280294,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:42.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84686,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015363/ownership.xml","form_type":"4"}},{"id":1280293,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:42.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":84686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units (\"PSUs\") granted on January 31, 2023, pursuant to the terms of the Merger Agreement."}],"balance_after":84686,"source":{"system":"sec-edgar","filing":"0000950170-25-015363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015363/ownership.xml","form_type":"4"}},{"id":1280292,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:42.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015363/ownership.xml","form_type":"4"}},{"id":1280291,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:42.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":110913,"price":3.65,"value":404832.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015363/ownership.xml","form_type":"4"}},{"id":1280290,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-02-06T15:59:42.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":996935,"price":3.65,"value":3638812.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":27933,"source":{"system":"sec-edgar","filing":"0000950170-25-015363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015363/ownership.xml","form_type":"4"}},{"id":1281777,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-05T19:53:49.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":27933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 2025, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2024 through December 31, 2024, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date."}],"balance_after":1024868,"source":{"system":"sec-edgar","filing":"0000950170-25-014825","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025014825/ownership.xml","form_type":"4"}},{"id":1314558,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-01-03T16:33:44.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":2.1845,"value":2184.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":996935,"source":{"system":"sec-edgar","filing":"0001479290-25-000004","document":"wk-form4_1735940017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929025000004/wk-form4_1735940017.xml","form_type":"4"}},{"id":1462916,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-07-02T17:47:39.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":2.1845,"value":2184.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":995935,"source":{"system":"sec-edgar","filing":"0001479290-24-000104","document":"wk-form4_1719956853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000104/wk-form4_1719956853.xml","form_type":"4"}},{"id":1494914,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T00:56:16.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":1246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date."}],"balance_after":1246,"derivative":{"exercise_price":110.7,"exercise_date":"2025-05-30","expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":1246},"source":{"system":"sec-edgar","filing":"0001415889-24-015236","document":"form4-06042024_120612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924015236/form4-06042024_120612.xml","form_type":"4"}},{"id":1494913,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T00:56:16.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":1716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,946 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":34936,"source":{"system":"sec-edgar","filing":"0001415889-24-015236","document":"form4-06042024_120612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924015236/form4-06042024_120612.xml","form_type":"4"}},{"id":1568511,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-19T18:43:19.000Z","date":"2024-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":17228,"price":5.305,"value":91394.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the performance-based restricted stock units (\"PSUs\") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals."}],"balance_after":994935,"source":{"system":"sec-edgar","filing":"0001479290-24-000065","document":"wk-form4_1710888177.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000065/wk-form4_1710888177.xml","form_type":"4"}},{"id":1568510,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-19T18:43:19.000Z","date":"2024-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":3305,"price":5.305,"value":17533.025,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the \"RSA\") for 13,572 shares. The RSA vested in three equal annual installments from March 15,\n2021."}],"balance_after":1012163,"source":{"system":"sec-edgar","filing":"0001479290-24-000065","document":"wk-form4_1710888177.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000065/wk-form4_1710888177.xml","form_type":"4"}},{"id":1586640,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-08T16:33:10.000Z","date":"2024-03-06","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":6.98,"value":209400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person purchased shares of common stock in an underwritten public offering by the issuer that closed on March 6, 2024."}],"balance_after":1015468,"source":{"system":"sec-edgar","filing":"0001479290-24-000056","document":"wk-form4_1709933576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000056/wk-form4_1709933576.xml","form_type":"4"}},{"id":1602919,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-04T16:33:28.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":70750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.  On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest  based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024."}],"balance_after":985468,"source":{"system":"sec-edgar","filing":"0001479290-24-000050","document":"wk-form4_1709587601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000050/wk-form4_1709587601.xml","form_type":"4"}},{"id":1618955,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-27T00:01:08.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Granted July 10, 2014. Vested 1/3 annually over a three-year period such that it vested in full on the three-year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":7.275,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-005327","document":"form4-02272024_120257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924005327/form4-02272024_120257.xml","form_type":"4"}},{"id":1618954,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T00:01:08.000Z","date":"2024-02-23","kind":"sale","planned":false,"acquired":false,"shares":4560,"price":92.87,"value":423487.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $92.75 to $92.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,230 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":33220,"source":{"system":"sec-edgar","filing":"0001415889-24-005327","document":"form4-02272024_120257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924005327/form4-02272024_120257.xml","form_type":"4"}},{"id":1618953,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T00:01:08.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":7.275,"value":72750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,230 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":37780,"source":{"system":"sec-edgar","filing":"0001415889-24-005327","document":"form4-02272024_120257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588924005327/form4-02272024_120257.xml","form_type":"4"}},{"id":1661575,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Performance Stock Units","published_at":"2024-02-02T16:45:33.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":1070001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of  securities reported represents the maximum shares that can be earned."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is\ncontingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with  the Company through the vesting dates."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of  securities reported represents the maximum shares that can be earned."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of  securities reported represents the maximum shares that can be earned."}],"balance_after":1070001,"derivative":{"exercise_date":"2025-02-15","expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":1070001},"source":{"system":"sec-edgar","filing":"0001479290-24-000014","document":"wk-form4_1706910313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000014/wk-form4_1706910313.xml","form_type":"4"}},{"id":1692229,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-01-03T16:47:30.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":264,"price":7.47,"value":1972.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":914718,"source":{"system":"sec-edgar","filing":"0001479290-24-000004","document":"wk-form4_1704318430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000004/wk-form4_1704318430.xml","form_type":"4"}},{"id":1807295,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-08-15T16:15:45.000Z","date":"2023-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":48064,"price":18.91,"value":908890.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA."}],"balance_after":914454,"source":{"system":"sec-edgar","filing":"0001479290-23-000096","document":"wf-form4_169213053217251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000096/wf-form4_169213053217251.xml","form_type":"4"}},{"id":1807294,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-08-15T16:15:45.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":122143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date."}],"balance_after":962518,"source":{"system":"sec-edgar","filing":"0001479290-23-000096","document":"wf-form4_169213053217251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000096/wf-form4_169213053217251.xml","form_type":"4"}},{"id":1814873,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-08-04T17:07:53.000Z","date":"2023-08-03","kind":"sale","planned":true,"acquired":false,"shares":26279,"price":22.5713,"value":593151.1927,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $21.93 to $22.83. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":840375,"source":{"system":"sec-edgar","filing":"0001479290-23-000084","document":"wf-form4_169118325849807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000084/wf-form4_169118325849807.xml","form_type":"4"}},{"id":1836057,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-07-05T21:11:06.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":26279,"price":24.9375,"value":655332.5625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.73 to $25.19. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":866654,"source":{"system":"sec-edgar","filing":"0001479290-23-000081","document":"wf-form4_168860585515884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000081/wf-form4_168860585515884.xml","form_type":"4"}},{"id":1836056,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-07-05T21:11:06.000Z","date":"2023-06-30","kind":"grant","planned":true,"acquired":true,"shares":1000,"price":15.606,"value":15606.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":892933,"source":{"system":"sec-edgar","filing":"0001479290-23-000081","document":"wf-form4_168860585515884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000081/wf-form4_168860585515884.xml","form_type":"4"}},{"id":1857167,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-06-13T20:09:32.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":31279,"price":30.7212,"value":960928.4148,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $30.16 to $31.13. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":891933,"source":{"system":"sec-edgar","filing":"0001479290-23-000078","document":"wf-form4_168670135753126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000078/wf-form4_168670135753126.xml","form_type":"4"}},{"id":1866578,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-06T00:14:04.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":3230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,542 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":27780,"source":{"system":"sec-edgar","filing":"0001415889-23-009293","document":"form4-06062023_120601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588923009293/form4-06062023_120601.xml","form_type":"4"}},{"id":1891452,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-16T20:29:16.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":70447,"price":34.5469,"value":2433725.4643,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":923212,"source":{"system":"sec-edgar","filing":"0001479290-23-000074","document":"wf-form4_168428334405537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000074/wf-form4_168428334405537.xml","form_type":"4"}},{"id":1891451,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-16T20:29:16.000Z","date":"2022-02-02","kind":"grant","planned":false,"acquired":true,"shares":175649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents settlement of a performance-based restricted stock unit (\"PSU\") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock."}],"balance_after":993659,"source":{"system":"sec-edgar","filing":"0001479290-23-000074","document":"wf-form4_168428334405537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000074/wf-form4_168428334405537.xml","form_type":"4"}},{"id":1946891,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-17T15:22:10.000Z","date":"2023-03-15","kind":"tax_withholding","acquired":false,"shares":5341,"price":30.65,"value":163701.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the\"RSA\") for 13,572 shares. The RSA vests in three equal annual installments from March 15, 2021."}],"balance_after":818010,"source":{"system":"sec-edgar","filing":"0001479290-23-000042","document":"wf-form4_167908091716141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000042/wf-form4_167908091716141.xml","form_type":"4"}},{"id":1960913,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-09T21:45:39.000Z","date":"2023-03-09","kind":"sale","acquired":false,"shares":70390,"price":31.5863,"value":2223359.657,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":823351,"source":{"system":"sec-edgar","filing":"0001479290-23-000034","document":"wf-form4_167841632767102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000034/wf-form4_167841632767102.xml","form_type":"4"}},{"id":1960912,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-09T21:45:39.000Z","date":"2022-09-22","kind":"grant","acquired":true,"shares":175649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents settlement of a performance-based restricted stock unit (\"PSU\") granted on February 2, 2022. On September 22, 2022, the Company's Compensation Committee certified 100% of the PSUs eligible to vest based on i) the achievement of the U.S. Food and Drug Administration's (\"FDA\") approval of the Issuer's biologics license application (BLA) for DAXXIFY(R) for the improvement of glabellar lines (\"FDA Approval\") and ii) subject to the Reporting Person remaining in continuous service through the six-month anniversary following the date of the FDA Approval which six-month anniversary was March 7, 2023."}],"balance_after":893741,"source":{"system":"sec-edgar","filing":"0001479290-23-000034","document":"wf-form4_167841632767102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000034/wf-form4_167841632767102.xml","form_type":"4"}},{"id":2066385,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T22:58:00.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":2948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the\nIssuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of\nthe Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,312 restricted stock units that have not vested or been delivered to the Reporting Person."}],"balance_after":24550,"source":{"system":"sec-edgar","filing":"0001415889-23-000386","document":"form4-01042023_100145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000141588923000386/form4-01042023_100145.xml","form_type":"4"}},{"id":2072530,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-01-03T16:28:22.000Z","date":"2022-12-31","kind":"grant","acquired":true,"shares":605,"price":12.1805,"value":7369.2025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":718092,"source":{"system":"sec-edgar","filing":"0001479290-23-000001","document":"wf-form4_167278127879359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000001/wf-form4_167278127879359.xml","form_type":"4"}},{"id":2137041,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-10-14T19:02:33.000Z","date":"2022-10-13","kind":"tax_withholding","acquired":false,"shares":49274,"price":26.97,"value":1328919.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards (\"RSA's\") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":717487,"source":{"system":"sec-edgar","filing":"0001479290-22-000087","document":"wf-form4_166578850300322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000087/wf-form4_166578850300322.xml","form_type":"4"}},{"id":2214609,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-05T18:15:38.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":1000,"price":11.747,"value":11747.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":766761,"source":{"system":"sec-edgar","filing":"0001479290-22-000074","document":"wf-form4_165705932190547.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000074/wf-form4_165705932190547.xml","form_type":"4"}},{"id":2241581,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:55:38.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,232 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":21602,"source":{"system":"sec-edgar","filing":"0001104659-22-068667","document":"tm2217841-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465922068667/tm2217841-5_4seq1.xml","form_type":"4"}},{"id":2327317,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-17T17:54:02.000Z","date":"2022-03-15","kind":"tax_withholding","acquired":false,"shares":3304,"price":15.79,"value":52170.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the \"RSA\") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":765761,"source":{"system":"sec-edgar","filing":"0001209191-22-019723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919122019723/doc4.xml","form_type":"4"}},{"id":2411651,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-04T20:35:34.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":143354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":143354,"derivative":{"exercise_price":13.08,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":143354},"source":{"system":"sec-edgar","filing":"0001479290-22-000015","document":"wf-form4_164402491298660.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000015/wf-form4_164402491298660.xml","form_type":"4"}},{"id":2443245,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T01:55:44.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":2486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,868 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":17238,"source":{"system":"sec-edgar","filing":"0001104659-22-001661","document":"tm221974-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465922001661/tm221974-1_4seq1.xml","form_type":"4"}},{"id":2493206,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-11-29T21:24:09.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":40000,"price":12.8981,"value":515924.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $12.76 to $13.0305. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002."}],"balance_after":110913,"source":{"system":"sec-edgar","filing":"0001479290-21-000169","document":"wf-form4_163823903263601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000169/wf-form4_163823903263601.xml","form_type":"4"}},{"id":2541628,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-10-15T20:00:29.000Z","date":"2021-10-13","kind":"tax_withholding","acquired":false,"shares":42096,"price":23.08,"value":971575.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards (\"RSA's\") for 400,000 shares.  The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":769065,"source":{"system":"sec-edgar","filing":"0001479290-21-000158","document":"wf-form4_163434239998355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000158/wf-form4_163434239998355.xml","form_type":"4"}},{"id":2644535,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-07-02T19:52:10.000Z","date":"2021-06-30","kind":"other","acquired":true,"shares":882,"price":24.089,"value":21246.498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":811161,"source":{"system":"sec-edgar","filing":"0001479290-21-000130","document":"wf-form4_162526991461391.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000130/wf-form4_162526991461391.xml","form_type":"4"}},{"id":2679018,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T23:04:25.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":2382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,566 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":14752,"source":{"system":"sec-edgar","filing":"0001104659-21-077837","document":"tm2119039-5_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465921077837/tm2119039-5_4seq.xml","form_type":"4"}},{"id":2879147,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-04T21:10:11.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":73665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Foley's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":73665,"derivative":{"exercise_price":28.01,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":73665},"source":{"system":"sec-edgar","filing":"0001479290-21-000028","document":"wf-form4_161249099366159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000028/wf-form4_161249099366159.xml","form_type":"4"}},{"id":2879146,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-04T21:10:11.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":40715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":810279,"source":{"system":"sec-edgar","filing":"0001479290-21-000028","document":"wf-form4_161249099366159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000028/wf-form4_161249099366159.xml","form_type":"4"}},{"id":2915044,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-07T02:30:01.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":1184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,084 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":12370,"source":{"system":"sec-edgar","filing":"0001104659-21-001753","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465921001753/a4.xml","form_type":"4"}},{"id":3006268,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-10-15T18:57:21.000Z","date":"2020-10-13","kind":"tax_withholding","acquired":false,"shares":66106,"price":27.62,"value":1825847.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (\"RSA\") for 133,332 shares.  The RSA vests in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":769564,"source":{"system":"sec-edgar","filing":"0001628280-20-014509","document":"wf-form4_160280262897368.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014509/wf-form4_160280262897368.xml","form_type":"4"}},{"id":3006267,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-10-15T18:57:21.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":50913,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2020. the Issuer completed acquisition (the \"Merger\") of Hint, Inc. (\"HintMD\") pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020, by and among the Issuer, HeartMerger Sub, Inc., direct wholly-owned subsidiary of the Issuer, HintMD, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by Mr. Foley and the Foley Family Trust in HintMD were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002."}],"balance_after":70913,"source":{"system":"sec-edgar","filing":"0001628280-20-014509","document":"wf-form4_160280262897368.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014509/wf-form4_160280262897368.xml","form_type":"4"}},{"id":3006266,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-10-15T18:57:21.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":264439,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2020. the Issuer completed acquisition (the \"Merger\") of Hint, Inc. (\"HintMD\") pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020, by and among the Issuer, HeartMerger Sub, Inc., direct wholly-owned subsidiary of the Issuer, HintMD, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by Mr. Foley and the Foley Family Trust in HintMD were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":835670,"source":{"system":"sec-edgar","filing":"0001628280-20-014509","document":"wf-form4_160280262897368.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014509/wf-form4_160280262897368.xml","form_type":"4"}},{"id":3016207,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-10-02T20:33:58.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":143269,"price":25.14,"value":3601782.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on September 30, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA."}],"balance_after":571231,"source":{"system":"sec-edgar","filing":"0001628280-20-014244","document":"wf-form4_160168522471281.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014244/wf-form4_160168522471281.xml","form_type":"4"}},{"id":3016206,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-10-02T20:33:58.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":301000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock received upon partial settlement of a performance share award (the \"PSA\") on September 30, 2020."}],"balance_after":714500,"source":{"system":"sec-edgar","filing":"0001628280-20-014244","document":"wf-form4_160168522471281.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000162828020014244/wf-form4_160168522471281.xml","form_type":"4"}},{"id":3105421,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T23:10:31.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":8797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a\ncontingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":8797,"source":{"system":"sec-edgar","filing":"0001562180-20-004591","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1459839/000156218020004591/primarydocument.xml","form_type":"4"}},{"id":3120082,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-06T01:51:12.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,900 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":11186,"source":{"system":"sec-edgar","filing":"0001127602-20-019061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000112760220019061/form4.xml","form_type":"4"}},{"id":3302954,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-01-24T20:22:45.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":413500,"source":{"system":"sec-edgar","filing":"0001479290-20-000021","document":"wf-form4_157991534708581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000021/wf-form4_157991534708581.xml","form_type":"4"}},{"id":3393644,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-10-15T20:23:04.000Z","date":"2019-10-13","kind":"grant","acquired":true,"shares":740000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The fair market value was determined on October 11,2019 pursuant to the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Option vests in accordance to the following schedule: 25% of the shares subject to the Option shall vest on the first anniversary of the vesting commencement date of October 13, 2019, and 1/48th of the shares vesting each month thereafter for the remaining three years,  subject to Mr. Foley's Continuous Service (as defined in the Plan) as of each such vesting date."}],"balance_after":740000,"derivative":{"exercise_price":12.18,"expiration_date":"2029-10-12","underlying":"Common Stock","underlying_shares":740000},"source":{"system":"sec-edgar","filing":"0001479290-19-000103","document":"wf-form4_157118535567459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000103/wf-form4_157118535567459.xml","form_type":"4"}},{"id":3393643,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2019-10-15T20:23:04.000Z","date":"2019-10-13","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) on each vesting date."}],"balance_after":213500,"source":{"system":"sec-edgar","filing":"0001479290-19-000103","document":"wf-form4_157118535567459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000103/wf-form4_157118535567459.xml","form_type":"4"}},{"id":3487658,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2019-06-17T23:41:45.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":26236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in a series of 36 equal monthly increments over three years starting on the Vesting Commencement Date, such that the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Issuer's Board of Directors on each applicable vesting date."}],"balance_after":26236,"derivative":{"exercise_price":17.72,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":26236},"source":{"system":"sec-edgar","filing":"0001562180-19-003577","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1459839/000156218019003577/primarydocument.xml","form_type":"4"}},{"id":3506152,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-01T00:06:19.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":2653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,653 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":7286,"source":{"system":"sec-edgar","filing":"0001104659-19-033243","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000110465919033243/a4.xml","form_type":"4"}},{"id":3531498,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-05-10T20:52:54.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":18000,"derivative":{"exercise_price":12.82,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001479290-19-000054","document":"wf-form4_155753595933818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000054/wf-form4_155753595933818.xml","form_type":"4"}},{"id":3531497,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T20:52:54.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Foley's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001479290-19-000054","document":"wf-form4_155753595933818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000054/wf-form4_155753595933818.xml","form_type":"4"}},{"id":3910468,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T20:35:54.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":4633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 4,633 restricted stock units that have not yet vested or been delivered to the Reporting Person."}],"balance_after":4633,"source":{"system":"sec-edgar","filing":"0001562180-18-002763","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000156218018002763/primarydocument.xml","form_type":"4"}},{"id":3937010,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-05-11T20:26:40.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":6000,"derivative":{"exercise_price":29.15,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001479290-18-000077","document":"wf-form4_152608473930197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000077/wf-form4_152608473930197.xml","form_type":"4"}},{"id":3937009,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-11T20:26:40.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Foley's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001479290-18-000077","document":"wf-form4_152608473930197.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000077/wf-form4_152608473930197.xml","form_type":"4"}},{"id":4131431,"issuer":{"id":3510,"kind":"organization","name":"GLAUKOS Corp","symbol":"GKOS"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-12-14T23:39:02.000Z","date":"2017-12-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's 2015 Omnibus Incentive Compensation Plan. Vests in full on May 31, 2018."}],"balance_after":15000,"derivative":{"exercise_price":25.77,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-17-003880","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192448/000156218017003880/primarydocument.xml","form_type":"4"}},{"id":4167660,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-09T19:47:44.000Z","date":"2017-11-07","kind":"purchase","acquired":true,"shares":500,"price":27.45,"value":13725.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-17-060104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117060104/doc4.xml","form_type":"4"}},{"id":4167659,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-09T19:47:44.000Z","date":"2017-11-07","kind":"purchase","acquired":true,"shares":19500,"price":26.9458,"value":525443.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Table I, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.425 to $27.425. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002."}],"balance_after":19500,"source":{"system":"sec-edgar","filing":"0001209191-17-060104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117060104/doc4.xml","form_type":"4"}},{"id":4214698,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-09-07T20:44:18.000Z","date":"2017-09-05","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option  shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date."}],"balance_after":12000,"derivative":{"exercise_price":24.55,"expiration_date":"2027-09-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-17-012138","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000117911017012138/edgar.xml","form_type":"4"}},{"id":4214697,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-07T20:44:18.000Z","date":"2017-09-05","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award (the \"RSA\").  The shares underlying the RSA shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive  Plan (the \"Plan\") through such vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001179110-17-012138","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000117911017012138/edgar.xml","form_type":"4"}},{"id":4342019,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":72254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":40.89,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":72254},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342018,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":124610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":23.03,"expiration_date":"2026-02-27","underlying":"Common Stock","underlying_shares":124610},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342017,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":26277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":34.65,"expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":26277},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342016,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2024-02-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342015,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":121236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2022-04-27","underlying":"Common Stock","underlying_shares":121236},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342014,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":9536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":5.06,"expiration_date":"2022-06-14","underlying":"Common Stock","underlying_shares":9536},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342013,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":758667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":5.04,"expiration_date":"2022-08-23","underlying":"Common Stock","underlying_shares":758667},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342012,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":572435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":5.04,"expiration_date":"2022-08-23","underlying":"Common Stock","underlying_shares":572435},"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4342011,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-04-28T13:28:20.000Z","date":"2017-04-28","kind":"disposition_to_issuer","acquired":false,"shares":173787,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved by the board of directors of the Issuer (the \"Board\"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the \"Merger\"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved by the board of directors of the Issuer (the \"Board\"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the \"Merger\"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-028606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028606/doc4.xml","form_type":"4"}},{"id":4353404,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-04-12T11:27:14.000Z","date":"2017-04-07","kind":"gift","acquired":false,"shares":37667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":173787,"source":{"system":"sec-edgar","filing":"0001209191-17-026639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117026639/doc4.xml","form_type":"4"}},{"id":4386258,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-14T10:59:56.000Z","date":"2017-03-13","kind":"gift","acquired":false,"shares":8976,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":211454,"source":{"system":"sec-edgar","filing":"0001209191-17-020383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117020383/doc4.xml","form_type":"4"}},{"id":4386257,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-14T10:59:56.000Z","date":"2017-03-13","kind":"sale","acquired":false,"shares":10000,"price":55.7659,"value":557659.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.735 to $55.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":220430,"source":{"system":"sec-edgar","filing":"0001209191-17-020383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117020383/doc4.xml","form_type":"4"}},{"id":4421247,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-27T18:02:11.000Z","date":"2017-02-24","kind":"tax_withholding","acquired":false,"shares":4565,"price":55.62,"value":253905.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 24, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the \"RSUs\") granted on February 24, 2014 for 35,000 shares. The RSUs vested with respect to 25% of the underlying shares on February 24, 2015 and the remaining shares shall vest annually at a rate of 25% per year, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":230430,"source":{"system":"sec-edgar","filing":"0001209191-17-014926","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117014926/doc4.xml","form_type":"4"}},{"id":4431315,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-22T15:36:48.000Z","date":"2017-02-19","kind":"tax_withholding","acquired":false,"shares":7843,"price":55.67,"value":436619.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 19, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted on February 29, 2016 for 65,421 shares. The RSUs vest annually at a rate of 25% per year beginning from February 19, 2016, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":234995,"source":{"system":"sec-edgar","filing":"0001209191-17-013120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117013120/doc4.xml","form_type":"4"}},{"id":4431314,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-22T15:36:48.000Z","date":"2017-02-19","kind":"tax_withholding","acquired":false,"shares":4962,"price":55.67,"value":276234.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on February 19, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the \"RSUs\") granted on February 19, 2015 for 52,554 shares. The RSUs vest as follows: 25% of the total number of shares subject to the restricted stock units vested on February 19, 2016, and the remainder vest annually at a rate of 25% per year, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":242838,"source":{"system":"sec-edgar","filing":"0001209191-17-013120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117013120/doc4.xml","form_type":"4"}},{"id":4445420,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-15T13:34:31.000Z","date":"2017-02-13","kind":"sale","acquired":false,"shares":10000,"price":55.6871,"value":556871.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.5550 to $55.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":247800,"source":{"system":"sec-edgar","filing":"0001209191-17-010985","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117010985/doc4.xml","form_type":"4"}},{"id":4485178,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-20T19:06:20.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":72254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares subject to the option vest on January 18, 2018, and the remainder vest in equal monthly installments over a 36-month period thereafter, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":72254,"derivative":{"exercise_price":40.89,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":72254},"source":{"system":"sec-edgar","filing":"0001209191-17-004984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117004984/doc4.xml","form_type":"4"}},{"id":4485177,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-20T19:06:20.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":37861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments, with the vesting commencement date of January 18, 2017."}],"balance_after":257800,"source":{"system":"sec-edgar","filing":"0001209191-17-004984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117004984/doc4.xml","form_type":"4"}},{"id":4489835,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-17T11:10:20.000Z","date":"2017-01-13","kind":"sale","acquired":false,"shares":10000,"price":41.717,"value":417170.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $41.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":219939,"source":{"system":"sec-edgar","filing":"0001209191-17-003817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117003817/doc4.xml","form_type":"4"}},{"id":4520470,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":35933,"kind":"person","name":"Foley Mark J","position":1,"cik":"0001529196","reported_name":"Foley Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-15T11:20:23.000Z","date":"2016-12-14","kind":"gift","acquired":false,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":229939,"source":{"system":"sec-edgar","filing":"0001209191-16-155302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919116155302/doc4.xml","form_type":"4"}}],"next_cursor":"2016-12-15T11:20:23.000000Z,4520470"}